IHE vs XLV

Key Takeaways

• IHE offers targeted exposure to U.S. pharmaceuticals (99.9% allocation), while XLV provides broader healthcare coverage across pharmaceuticals (37%), providers (19%), biotech (18%), equipment (17%), and life sciences (9%).
• Both ETFs exhibit low expense ratios—IHE at 0.38% and XLV at 0.08%—with XLV benefiting from superior cost efficiency and massive scale ($37B AUM vs. IHE's $870M).
• IHE holds 55 stocks with top 10 comprising ~75% (led by LLY 22%, JNJ 21%); XLV has 60 holdings with top 10 at ~59% (led by LLY 15%, JNJ 10%).
• XLV demonstrates higher liquidity (avg daily volume ~2.5M shares, 0.01% bid-ask spread) compared to IHE (~100K shares, 0.09% spread), suiting larger investors.
• In recent market cycles, IHE has shown higher volatility (beta ~0.57, std dev 16%) driven by pharma concentration, while XLV offers more stable relative positioning (beta ~0.58).
• Both passive index trackers, but IHE suits pharma-thematic bets amid drug innovation; XLV favors diversified defensive healthcare exposure.

Introduction

Comparing IHE and XLV highlights key choices in healthcare ETF investing. IHE delivers pure-play pharmaceuticals exposure, capitalizing on drug development and innovation cycles. XLV, meanwhile, spans the full healthcare spectrum from the S&P 500, blending pharma with providers, biotech, and devices for balanced sector access. These ETFs appeal to investors seeking defensive growth amid economic uncertainty, sector rotation toward healthcare, and rising demand from aging demographics. While overlapping in top holdings like Eli Lilly and Johnson & Johnson, their structural differences—IHE's concentration versus XLV's diversification—offer alternative paths to similar goals: resilient returns with lower cyclical risk than broader markets.

iShares U.S. Pharmaceuticals ETF (IHE) Overview

The iShares U.S. Pharmaceuticals ETF (IHE) is a passive fund seeking to track the Dow Jones U.S. Select Pharmaceuticals Index, comprising U.S. equities manufacturing prescription drugs, over-the-counter medications, or vaccines. Launched in 2006, it holds 55 stocks with an expense ratio of 0.38% and approximately $870 million in assets under management (AUM). Top holdings dominate: LLY (Eli Lilly, 21.8%), JNJ (Johnson & Johnson, 20.9%), VTRS (Viatris, 5.5%), RPRX (Royalty Pharma, 5.0%), and MRK (Merck, 4.4%), accounting for ~75% of assets. Sector allocation is nearly 100% pharmaceuticals. With a 30-day median bid-ask spread of 0.09% and average daily volume around 100,000 shares, IHE provides targeted liquidity for thematic pharma exposure.

State Street Health Care Select Sector SPDR ETF (XLV) Overview

The State Street Health Care Select Sector SPDR ETF (XLV), launched in 1998, tracks the Health Care Select Sector Index, representing S&P 500 healthcare firms. This passive ETF has a low 0.08% expense ratio and $37 billion AUM. It holds 60 stocks, with top weights: LLY (14.8%), JNJ (10.3%), ABBV (AbbVie, 6.9%), UNH (UnitedHealth, 6.7%), and MRK (5.3%), totaling ~59%. Subsector breakdown: pharmaceuticals (37%), health care providers & services (19%), biotechnology (18%), equipment & supplies (17%), life sciences tools (9%). Exceptional liquidity shines with ~2.5 million average daily volume and 0.01% bid-ask spread.

Industry and Thematic Backdrop

Healthcare remains a defensive pillar amid macroeconomic shifts, bolstered by aging populations, chronic disease prevalence, and innovation in GLP-1 drugs, gene therapies, and AI diagnostics. Recent capital flows into sector ETFs reached multi-year highs late 2025, signaling rebound potential into 2026. Pharmaceuticals face drug pricing scrutiny but benefit from patent cliffs and M&A waves; broader healthcare navigates regulatory reforms at the FDA (U.S. Food and Drug Administration), reimbursement policies, and biotech funding resurgence. Risks include policy changes, geopolitical supply chain tensions, and competition from emerging markets. Catalysts like clinical trial successes and earnings from top holdings drive momentum, with sector rotation favoring healthcare during uncertainty.

Performance and Positioning Comparison

In recent months, IHE has outperformed XLV year-to-date (YTD ~3% vs. -7%), fueled by heavy weighting in high-flying pharma leaders like Eli Lilly amid GLP-1 demand and oncology advances. Over longer cycles, XLV edges ahead (10-year annualized ~9% vs. IHE's 8%), reflecting diversified buffers from providers like UnitedHealth during market drawdowns. IHE's pharma focus amplifies volatility (3-year std dev ~16%, beta 0.57), tying returns to earnings cycles and patent news, while XLV's broader exposure yields steadier positioning (beta ~0.58, lower drawdowns). Relative strength favors IHE in pharma momentum phases but shifts to XLV amid sector-wide rotations or interest rate stability.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to uncover hidden gems in healthcare or beyond.

Tickeron AI Verdict

Tickeron’s AI favors XLV with moderate conviction (~65% probability) for most investors. Its superior cost efficiency (0.08% expense ratio), extensive diversification (60 holdings, multi-subsector), massive liquidity, and consistent trend alignment across cycles outweigh IHE's recent pharma momentum. While IHE suits concentrated bets on drug innovation, XLV's structural resilience and lower risk exposure position it better amid regulatory uncertainties and sector rotations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations